SECTOR: HEALTHCARE; SOFTWARE & SERVICES
Motif announced it will be presenting at the following two conferences in March 2018.
Superbugs & Superdrugs 2018 (March 19-20, London, UK): David Huang, Chief Medical Officer, will give a presentation on iclaprim, the Company’s lead antibiotic drug candidate, at 12:10pm on Tuesday, March 20th. Link to conference site: here.
Oppenheimer 28th Annual Healthcare Conference (March 20-21, New York, NY): Graham Lumsden, Chief Executive Officer, will give a corporate presentation at 11:30am on Wednesday, March 21st. Link to conference website here.
These two conferences provide a platform for the Company to meet with leaders from pharmaceutical companies, academia, regulatory agencies and investors. In 2017, Motif completed two Phase 3 trials testing iclaprim, its lead antibiotic candidate, in acute bacterial skin and skin structure infection (ABSSSI).
The Company is focusing on submitting a new drug application (NDA) for the use of iclaprim in ABSSSI to the US FDA in the first quarter of 2018. With a lead asset and two successful Phase 3 trials completed, Northland views Motif as significantly undervalued.
Clinical-stage biopharmaceutical company specialising in the development of novel antibiotics.
TechFinancials reported completion of its CEDEX token pre-sale event announced on 16th March, with sales of 25m CEDEX tokens, at 1ETH=900 CEDEX tokens, as planned.
Subsequently, the main sale started on 17th March at 10:00am and is scheduled to run to 17th April, or until the hard cap (total issuance of coin created) of 50m CEDEX tokens sold is achieved.
TechFinancials CEO, Asaf Lahav, commented: "We are excited to announce that the CEDEX pre-sale event has completed, using TechFinancials' technology, which has been developed over the past six months since we entered the blockchain market. Whilst offering CEDEX our proprietary technology, we are pleased to have been able to provide the company with a 360° solution in order to meet its operational needs."
As noted on 16th March, progress updates on the token sale are available at www.cedex.com, currently showing a total of 25,705,052 tokens sold amounting to a total contribution of US$20.211m.
TechFinancials is a leading technology provider to binary options brokers.